Innolake Biopharm has been awarded the “Best ADC Developer in China”title for the prestigious 2025 Asia-Pacific Biopharma Excellence Awards. Selected from 89 candidates across 12 Asia-Pacific countries, the company was recognized for its advanced ADC R&D capabilities, proprietary technology platform, and differentiated product pipeline. The award marks that Innolake Biopharm, as an emerging innovative biotech company in China, has gained international peer recognition for its leading position in the field of ADC research and development.

About ABEA

The Asia-Pacific Biopharma Excellence Awards 2025 seeks to give recognition to exceptional Asian biopharma experts, organisations, and technologies over the past year. The award ceremony recognises the outstanding achievements of top biopharma industry leaders. The Asia-Pacific Biopharma Excellence Awards applaud extraordinary leaders & trendsetters of today and inspire innovators of tomorrow. ABEA 2025 will take place on March 12th, 2025, at the Sands Expo & Convention Center, Singapore.

About Innolake

Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases and to improve life of patients around the world. Innolake is focusing on inventing & developing novel mAb/BsAb ADCs for oncology diseases, and antibody therapeutics (esp. BsAbs) for autoimmune and cancer immunotherapy.

The company debuted with a top-tier and enthusiastic scientific & clinical development team and $40 million Series Pre-A and successfully raised a $20 million Series A1 in 2023. Innolake places innovation at the cornerstone of its overall strategy. Through in-house R&D and partnering, Innolake has established a robust pipeline of FIC and BIC products, both clinical and preclinical stage. Innolake has strong industry recognition in China and abroad, and has been listed as one of most innovative biotech companies on several renowned biopharmaceutical industry innovation lists.